Stereotactic body radiotherapy for lung oligometastatic prostate cancer: An international retrospective multicenter study

IF 2.7 3区医学 Q3 ONCOLOGY

Clinical and Translational Radiation Oncology Pub Date : 2025-03-10 DOI:10.1016/j.ctro.2025.100944

Maximilien Rogé , Patrick Bowden , Paul Conway , Ciro Franzese , Marta Scorsetti , Emmanuel Seront , Pierre Blanchard , Mario Terlizzi , Jonathan Khalifa , Corentin Pasquier , Ulrike Shick , Shankar Siva , Julie Paul , Stéphane Supiot

{"title":"Stereotactic body radiotherapy for lung oligometastatic prostate cancer: An international retrospective multicenter study","authors":"Maximilien Rogé , Patrick Bowden , Paul Conway , Ciro Franzese , Marta Scorsetti , Emmanuel Seront , Pierre Blanchard , Mario Terlizzi , Jonathan Khalifa , Corentin Pasquier , Ulrike Shick , Shankar Siva , Julie Paul , Stéphane Supiot","doi":"10.1016/j.ctro.2025.100944","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Management of prostate cancer (PCa) patients with lung oligometastases remains unclear in the absence of published data.</div></div><div><h3>Objective</h3><div>The aim of this study was to evaluate the efficacy of Stereotactic Body Radiotherapy (SBRT) in this setting.</div></div><div><h3>Design, setting, and participants</h3><div>We conducted a multicenter retrospective study that included 35 PCa patients treated with SBRT for lung oligometastases in 7 centers across 3 countries.</div></div><div><h3>Outcome measurements and statistical analysis</h3><div>The efficacy was evaluated by the progression free-survival (PFS), defined as pre-SBRT PSA + 25 % or nadir PSA + 25 % and + 2 ng/mL or radiological progression if it occurred before biochemical progression. The local recurrence free-survival (LRFS), distant metastases free-survival (DMFS), Overall Survival (OS) and Androgen Deprivation Therapy free-survival were also assessed. Survival was estimated using the Kaplan Meier method.</div></div><div><h3>Results</h3><div>35 patients were included with lung oligometastases staged with PET-CT for 97 % and histologically biopsy confirmed for 51 %. 77 % had an oligorecurrent metastatic disease. The median pre SBRT PSA was at 1.7 ng/mL [0.8, 3.0] and the median follow-up after SBRT was 28.7 months. The median PFS was 21.6 months [95 %CI: 21.6; NA] and the median DMFS was 32.4 months [95 %CI: 22.2–NA]. No parameters were significantly associated with PFS on the univariate and multivariate models.</div><div>For patients who did not start ADT before or concomitantly with SBRT (n = 18), the 1-year ADT free-survival rate was estimated at 87.2 % [71.9;100].</div></div><div><h3>Conclusions</h3><div>SBRT for PCa lung oligometastases offers good oncological outcomes, comparable to those reported for bone and/or lymph node metastases SBRT. Our results encourage the inclusion of patients with lung oligometastatic disease in clinical trials designed to assess the value of SBRT.</div></div><div><h3>Patient summary</h3><div>SBRT for prostate cancer lung oligometastases shows promising results, similar to treatments for bone or lymph node oligometastases.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"52 ","pages":"Article 100944"},"PeriodicalIF":2.7000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405630825000345","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Management of prostate cancer (PCa) patients with lung oligometastases remains unclear in the absence of published data.

Objective

The aim of this study was to evaluate the efficacy of Stereotactic Body Radiotherapy (SBRT) in this setting.

Design, setting, and participants

We conducted a multicenter retrospective study that included 35 PCa patients treated with SBRT for lung oligometastases in 7 centers across 3 countries.

Outcome measurements and statistical analysis

The efficacy was evaluated by the progression free-survival (PFS), defined as pre-SBRT PSA + 25 % or nadir PSA + 25 % and + 2 ng/mL or radiological progression if it occurred before biochemical progression. The local recurrence free-survival (LRFS), distant metastases free-survival (DMFS), Overall Survival (OS) and Androgen Deprivation Therapy free-survival were also assessed. Survival was estimated using the Kaplan Meier method.

Results

35 patients were included with lung oligometastases staged with PET-CT for 97 % and histologically biopsy confirmed for 51 %. 77 % had an oligorecurrent metastatic disease. The median pre SBRT PSA was at 1.7 ng/mL [0.8, 3.0] and the median follow-up after SBRT was 28.7 months. The median PFS was 21.6 months [95 %CI: 21.6; NA] and the median DMFS was 32.4 months [95 %CI: 22.2–NA]. No parameters were significantly associated with PFS on the univariate and multivariate models.

For patients who did not start ADT before or concomitantly with SBRT (n = 18), the 1-year ADT free-survival rate was estimated at 87.2 % [71.9;100].

Conclusions

SBRT for PCa lung oligometastases offers good oncological outcomes, comparable to those reported for bone and/or lymph node metastases SBRT. Our results encourage the inclusion of patients with lung oligometastatic disease in clinical trials designed to assess the value of SBRT.